37 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
Protocol Assessment by FDA.
About Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer is a highly lethal form of cancer, and it is the fourth
8-K
EX-99.1
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
molecular therapy. The Company’s pivotal phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA.
About
8-K
EX-99.1
4mxti9 ywc4i38
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
EX-99.1
2mdnh udlf71e
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
xb3e9m6q4sua
6 Dec 22
Regulation FD Disclosure
8:01am
DEF 14A
p71jcg
2 Sep 22
Definitive proxy
8:30am
S-3
EX-4.8
t1ruyu
5 Aug 22
Shelf registration
5:08pm
S-3
EX-1.2
l243sf2v7bo1 g2q
5 Aug 22
Shelf registration
5:08pm